American Society of Hirudotherapy

Eptifibatide

Cyclic heptapeptide GP IIb/IIIa receptor antagonist — FDA approved 1998. Designed from snake-venom barbourin; not derived from the leech.

Studied off-label: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Last Updated: May 26, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • Eptifibatide0.83 kDa
Molecular weight (kilodaltons) of Eptifibatide (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Studied off-label: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.
Page type
Compound profile
Evidence type
Clinical and regulatory evidence (FDA-approved derived drug)
Evidence level
FDA-cleared regulatory context
Drug vs leech
Synthetic analog
Safety domains
Bleeding

Clinical translation limit

Eptifibatide is a synthetic cyclic heptapeptide designed from the KGD sequence of the snake-venom disintegrin barbourin (Scarborough 1991, 1993); it is not derived from leech decorsin. Its RCT evidence base (PURSUIT) applies only to the drug, not to whole medicinal-leech therapy.

Molecular Profile

Category
Antiplatelet
Evidence tier
Tier A — FDA-approved derivative
Molecular weight
831.96 Da
Source species
Synthetic peptidomimetic
Discovered
1993 · COR Therapeutics (designed from the KGD sequence of barbourin, a disintegrin from the venom of Sistrurus miliarius barbouri)
PubChem CID
123610
Derived FDA-approved drug
Integrilin (FDA approved May 1998)

Biological Targets

  • → platelet integrin αIIbβ3 (GP IIb/IIIa)

Key Citations

  1. Scarborough RM et al. (1991), J Biol Chem · PMID 2033037
  2. Scarborough RM et al. (1993), J Biol Chem · PMID 8419315
  3. PURSUIT Trial Investigators (1998), N Engl J Med · PMID 9705684

Related Antiplatelet Compounds

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.